The carnage in the biotech space in Q4 of last year was devastating to a lot of portfolios, and many of the stocks in the space became victims of aggressive...
Sarepta Therapeutics’ Eteplirsen Study Reveals Benefits to Patients (SRPT)
Sarepta Therapeutics (NASDAQ: SRPT), an RNA-based therapeutics company that develops drugs to treat serious, life-threatening, rare and infectious diseases, announced at the Action Duchenne meeting in London that patients treated...